Merck KGaA (MRK: DE) has reported strong financial results for the second quarter of 2024, driven largely by a robust performance in its life science business.
Healthcare achieved organic sales growth of 5.3%, bolstered by key products in its oncology and cardiovascular, metabolism, and endocrinology franchises.
Overall, Merck's group net sales increased organically by 1.7% to 5.4 billion euros ($5.93 billion) compared to the same quarter last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze